Chloroprocaine Hci Injection, Solution
NDC Package 51662-1401-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Chloroprocaine Hci injection is nesacaine 1% and 2% Injections, in multidose vials with methylparaben as preservative, are indicated for the production of local anesthesia by infiltration and peripheral nerve block. This formulation utilizes a injection, solution delivery system. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1401 and is authorized under FDA application NDA009435.

Identification & Billing

NDC Package Code
51662-1401-3
Package Description
21 POUCH in 1 CASE / 1 VIAL, MULTI-DOSE in 1 POUCH (51662-1401-2) / 30 mL in 1 VIAL, MULTI-DOSE
Product Code
51662-1401
11-Digit Billing Format
51662140103
RxNorm Crosswalk
  • RxCUI: 992805 - chloroprocaine HCl 2 % Injectable Solution
  • RxCUI: 992805 - chloroprocaine hydrochloride 20 MG/ML Injectable Solution
  • RxCUI: 992805 - chloroprocaine hydrochloride 2 % Injectable Solution

Clinical Specifications

Proprietary Name
Chloroprocaine Hci
Non-Proprietary Name
Chloroprocaine Hci
Substance Name
Chloroprocaine Hydrochloride
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
  • Infiltration - Administration that results in substances passing into tissue spaces or into cells.
  • Perineural - Administration surrounding a nerve or nerves.
Active Ingredient(s)
CHLOROPROCAINE HYDROCHLORIDE 20 mg/mL
Pharmacologic Class
Usage Information
Nesacaine 1% and 2% Injections, in multidose vials with methylparaben as preservative, are indicated for the production of local anesthesia by infiltration and peripheral nerve block. They are not to be used for lumbar or caudal epidural anesthesia.Nesacaine-MPF 2% and 3% Injections, in single dose vials without preservative and without EDTA, are indicated for the production of local anesthesia by infiltration, peripheral and central nerve block, including lumbar and caudal epidural blocks.Nesacaine and Nesacaine-MPF Injections are not to be used for subarachnoid administration.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co Llc, Dba Healthfirst
Product Type
Human Prescription Drug
FDA Application #
NDA009435
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-13-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (51662-1401). Click a package code to view its specific billing and regulatory data.

51662-1401-1
30 mL in 1 VIAL, MULTI-DOSE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1401-3 identifies a specific commercial package of 21 pouch in 1 case / 1 vial, multi-dose in 1 pouch (51662-1401-2) / 30 ml in 1 vial, multi-dose of Chloroprocaine Hci, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. This injection, solution is formulated for infiltration; perineural use and contains chloroprocaine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on October 13, 2019. The current certification is valid through December 31, 2026.

How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662140103. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1401-3
11-Digit CMS (5-4-2)
51662-1401-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.